Assertio Holdings, Inc. (ASRT)

In the past six months, Assertio Holdings, Inc. (ASRT) stock has experienced a general downward trend, declining by 10.88%. On December 22, 2025, Assertio Holdings, Inc. announced a 1-for-15 reverse stock split. In October 2025, Assertio Holdings appointed Director Mark Reisenauer to succeed Brendan O'Grady as CEO. The company reported strong financial results for the third quarter of 2025, significantly exceeding analyst expectations, propelled by a substantial increase in sales of Rolvedon. Brendan P. O'Grady resigned from the Board of Directors, effective November 17, 2025. On January 10, 2026, Assertio Holdings, Inc. announced the publication of its Rolvedon Same-Day Dosing Clinical Trial.

Specific detailed seasonal patterns for Assertio Holdings, Inc.'s products and services are not readily available without specialized access, but platforms like Seeking Alpha display mean and median monthly returns for ASRT to identify seasonal trends. Recent financial reports indicate that product sales can be influenced by factors beyond typical seasonality, such as inventory management and strategic distribution. Sales of products like Indocin have seen declines due to increased generic competition, while Sympazan sales showed modest growth.

Assertio Holdings, Inc. is a pharmaceutical company focused on developing and commercializing differentiated products in neurology, orphan and specialty medicines, hospital, and pain and inflammation. The company acquires or licenses approved products and leverages its commercial capabilities, including sales force, non-personal promotion models, payer contracting, and trade and distribution. Assertio's portfolio includes INDOCIN, Sympazan, CAMBIA, SPRIX, Otrexup, ROLVEDON, Gralise, and Zipsor.

Assertio Holdings, Inc. primarily provides its products to patients in the United States. The company's commercial reach is concentrated in North America, with plans to explore additional partnerships for international distribution.

Assertio Holdings has been undergoing a strategic transformation aimed at shifting from stabilization to growth, which includes efforts to enhance its brand reputation by reducing legal liabilities and focusing on high-margin, science-driven therapies. The company has actively worked to mitigate risks by settling high-profile cases and transferred opioid-related liabilities to a subsidiary. The company emphasizes its dedication to advancing patient care through differentiated products in neurology, oncology, hospital, and pain and inflammation. James L. Tyree, Chairman of the Compensation Committee, did not seek re-election in April 2024 due to disagreements over a potential exception to the Board's mandatory retirement policy and inaction on his proposal to raise the retirement age.

Assertio Holdings, Inc. has a significant number of institutional owners and shareholders. As of January 7, 2026, 91 institutional owners held a total of 25,743,027 shares. Major institutional owners include Nantahala Capital Management, LLC, Vanguard Group Inc, Renaissance Technologies Llc, BlackRock, Inc., Geode Capital Management, Llc, CM Management, LLC, Millennium Management Llc, Morgan Stanley, State Street Global Advisors, Inc., and Perritt Capital Management, Inc. Major individual owners include Gavin Molinelli, Biovail Laboratories Inc, Kevin C. Tang, James A. Schoeneck, and Arthur J. Higgins.